CGMP

ROSEN, A LONGSTANDING LAW FIRM, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SCYX

Retrieved on: 
Thursday, November 9, 2023
Class Action Lawsuit, Professional Services, Legal, Titan, Good manufacturing practice, CGMP, Court, I-Space (Chinese company), Advertising, Tablet, Risk, Class, Tobacco, Insurance

WHAT TO DO NEXT: To join the SCYNEXIS class action, go to https://rosenlegal.com/submit-form/?case_id=20281 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the SCYNEXIS class action, go to https://rosenlegal.com/submit-form/?case_id=20281 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against SCYNEXIS, Inc. (SCYX) Investors

Retrieved on: 
Thursday, November 9, 2023
Class Action Lawsuit, Professional Services, Legal, Suite, FDA, Good manufacturing practice, CGMP, Allergy, News, Court, Tablet, GPM, Risk, Hypersensitivity, Defendant, Cryptocurrency, Pharmaceutical industry

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • If you purchased or otherwise acquired Scynexis securities during the Class Period, you may move the Court no later than January 8, 2024 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 8, 2023
Research, Good manufacturing practice, Vaccine, Treatment, Pfizer, COVID-19, Immunity, Alpha, SARS-CoV-2, Matrix (biology), Biotechnology, Head, HIV, Immune system, Antibody, Cancer, University, Safety, Patient, D, Immunodeficiency, CGMP, Security (finance), Conference, Chronic lymphocytic leukemia, HNSCC, City, Growth, VP40, GeoVax, Patent, FDA, AACR, Protein structure, CLL, MVA, Atrium Health Wake Forest Baptist, Infection, ABL, Fred Hutchinson Cancer Research Center, Pharmaceutical industry, Cryptocurrency, Malaria, Omicron, Moderna

ET

Key Points: 
  • ET
    ATLANTA, GA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter ended September 30, 2023 and provided a business update.
  • GEO-CM04S1 demonstrated potent antibody and cellular immunity in immunocompromised patients in a recent publication in the journal, Vaccines, in August 2023.
  • Cash Position: GeoVax reported cash balances of $12,687,041 at September 30, 2023, as compared to $27,612,732 at December 31, 2023.
  • ET today, November 8, 2023, to review financial results and provide an update on corporate developments.

SCYNEXIS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against SCYNEXIS, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, November 9, 2023
Class Action Lawsuit, Professional Services, Legal, FDA, Good manufacturing practice, CGMP, Allergy, Person, Telephone, News, Court, P.C, Tablet, Jeanne Eagels, Risk, District court, Hypersensitivity, Defendant, Pharmaceutical industry

Investors have until January 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until January 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • On this news, the Company’s shares fell $1.13, or 34.14%, to close at $2.18 per share on September 25, 2023, on unusually heavy trading volume.
  • The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.

Class Action Lawsuit Filed Against SCYNEXIS, Inc. (SCYX) on Behalf of Investors – Nationally Ranked Investors’ Rights Firm Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

Retrieved on: 
Wednesday, November 8, 2023
Tablet, Good manufacturing practice, CGMP, Loss, Fraud, Risk, ISS

ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC informs investors that a shareholder class action lawsuit has been filed against SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) (NASDAQ: SCYX).

Key Points: 
  • ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC informs investors that a shareholder class action lawsuit has been filed against SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) (NASDAQ: SCYX).
  • at [email protected] , by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/scynexis/ to learn more.
  • Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021 and 2022, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation.
  • Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.

Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs

Retrieved on: 
Wednesday, November 8, 2023
Regenerative medicine, AAV, California Institute for Regenerative Medicine, Biotechnology, CDMO, Research, CGT, Partnership, CIRM, Patient, CGMP, Pharmaceutical industry

The collaboration is designed to support the advancement of manufacturing of adeno-associated adenovirus (AAV), as well as other cell and gene therapy (CGT) programs within the state of California.

Key Points: 
  • The collaboration is designed to support the advancement of manufacturing of adeno-associated adenovirus (AAV), as well as other cell and gene therapy (CGT) programs within the state of California.
  • Under terms of the partnership, Avid has joined the CIRM Industry Resource Partner Program to provide development and CGMP manufacturing services to CIRM-funded programs.
  • “CIRM was established with a mission to provide treatments to patients with unmet medical needs through the promise of cell and gene therapy.
  • “We are thrilled to welcome Avid Bioservices to our network of partners who share our unwavering commitment to advancing transformative regenerative medicine therapies for patients.”

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of SCYNEXIS, Inc. (SCYX) Investors

Retrieved on: 
Wednesday, November 8, 2023
Class Action Lawsuit, Professional Services, Legal, Suite, FDA, Good manufacturing practice, CGMP, Allergy, Person, News, Court, Law, Tablet, Risk, Hypersensitivity, Defendant, Cryptocurrency, Pharmaceutical industry

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired SCYNEXIS, Inc. (“Scynexis” or the “Company”) (NASDAQ: SCYX ) securities between March 31, 2023 and September 22, 2023, inclusive (the “Class Period”).

Key Points: 
  • The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired SCYNEXIS, Inc. (“Scynexis” or the “Company”) (NASDAQ: SCYX ) securities between March 31, 2023 and September 22, 2023, inclusive (the “Class Period”).
  • Scynexis investors have until January 8, 2024 to file a lead plaintiff motion.
  • If you are a shareholder who suffered a loss, click here to participate.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of SCYNEXIS, Inc. (SCYX) Investors

Retrieved on: 
Wednesday, November 8, 2023
Class Action Lawsuit, Professional Services, Legal, Suite, FDA, Good manufacturing practice, CGMP, Allergy, Telephone, News, Law, Tablet, Risk, Hypersensitivity, Defendant, Cryptocurrency, Pharmaceutical industry

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased SCYNEXIS, Inc. (“Scynexis” or the “Company”) (NASDAQ: SCYX ) securities between March 31, 2023 and September 22, 2023, inclusive (the “Class Period”).

Key Points: 
  • Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased SCYNEXIS, Inc. (“Scynexis” or the “Company”) (NASDAQ: SCYX ) securities between March 31, 2023 and September 22, 2023, inclusive (the “Class Period”).
  • Scynexis investors have until January 8, 2024 to file a lead plaintiff motion.
  • Investors suffering losses on their Scynexis investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

SCYX CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against SCYNEXIS, Inc.

Retrieved on: 
Wednesday, November 8, 2023
Class Action Lawsuit, Professional Services, Legal, Suite, FDA, Good manufacturing practice, CGMP, Allergy, Person, News, Court, Law, Tablet, Risk, District court, Hypersensitivity, Defendant, Pharmaceutical industry

The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the District of New Jersey, captioned Feldman v. SCYNEXIS, Inc., et al., Case No.

Key Points: 
  • The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the District of New Jersey, captioned Feldman v. SCYNEXIS, Inc., et al., Case No.
  • 23-cv-22082, on behalf of persons and entities that purchased or otherwise acquired SCYNEXIS, Inc. (“Scynexis” or the “Company”) (NASDAQ: SCYX ) securities between March 31, 2023 and September 22, 2023, inclusive (the “Class Period”).
  • Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).
  • Investors are hereby notified that they have until January 8, 2024 to move the Court to serve as lead plaintiff in this action.

SCYX CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against SCYNEXIS, Inc.

Retrieved on: 
Tuesday, November 7, 2023
Class Action Lawsuit, Professional Services, Legal, Suite, FDA, Good manufacturing practice, CGMP, Allergy, Person, News, Court, Tablet, GPM, Risk, District court, Hypersensitivity, Defendant, Medical device, Pharmaceutical industry

Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the District of New Jersey, captioned Feldman v. SCYNEXIS, Inc., et al., Case No.

Key Points: 
  • Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the District of New Jersey, captioned Feldman v. SCYNEXIS, Inc., et al., Case No.
  • 23-cv-22082, on behalf of persons and entities that purchased or otherwise acquired SCYNEXIS, Inc. (“Scynexis” or the “Company”) (NASDAQ: SCYX ) securities between March 31, 2023 and September 22, 2023, inclusive (the “Class Period”).
  • Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).
  • Investors are hereby notified that they have 60 days from the date of this notice to move the Court to serve as lead plaintiff in this action.